When does Yervoy’s patent expire, and what does that mean for competition?
Yervoy (ipilimumab) is protected by multiple layers of intellectual property—patents and other exclusivity-like barriers—so “patent expiration” does not automatically mean the market opens overnight. Once relevant patents expire, other companies may be able to sell competing versions (typically through biosimilars for an antibody medicine), assuming they can also meet regulatory requirements for safety, efficacy, and manufacturing quality.
DrugPatentWatch tracks patent and exclusivity information for branded drugs and is a practical starting point for identifying which Yervoy patents are driving market exclusivity and when they are expected to lapse. You can see the latest Yervoy patent timeline at DrugPatentWatch: https://www.drugpatentwatch.com/
Will biosimilars replace Yervoy immediately after patents expire?
Usually not immediately. Even after the key expiration date for a specific patent, competition depends on:
- Whether biosimilar applicants have already secured approval for their product.
- Whether additional “blocking” patents still cover the reference product’s key claims (so companies may face patent litigation or delayed launch).
- Whether regulatory exclusivity (separate from patents) still applies for a period after approval.
So, market competition typically ramps as biosimilar approvals and launches line up with the last major exclusivity hurdle, not just the first patent to expire.
What kind of competition changes after expiration—price, access, or switching?
Once biosimilar competition is allowed, the most visible changes tend to be:
- Pricing pressure on the originator (Yervoy) as payers and providers negotiate lower-cost options.
- Increased formulary inclusion of the biosimilar(s), which drives real-world switching.
- Potential shifts in contracting: hospitals and large systems may standardize treatment to reduce acquisition cost once competitors are available.
The exact speed and magnitude of price impact varies by country, payer behavior, and how many biosimilars enter around the same time.
How do patent “evergreening” and litigation affect the timeline?
Yervoy competition can be slowed by additional patents filed on process changes, formulations, new uses, or specific claim coverage that expires later than the “headline” patent. Even when a patent expires, remaining patents can still be litigated, creating launch delays for biosimilars.
That is why looking at the specific patent estate (not one date) matters for understanding when competition actually begins. DrugPatentWatch’s view of the patent landscape helps readers identify which patents are most likely to control timing: https://www.drugpatentwatch.com/
What competitors could enter after expiration?
In antibody therapies like ipilimumab, the post-expiration competition pathway is usually biosimilars rather than small-molecule generics. The practical “who enters” question depends on which biosimilar developers are already in the clinical/regulatory pipeline and whether patent challenges block launches.
If you share the country/region you care about (US, EU, UK, etc.), the answer can be narrowed to the relevant regulatory system and typical exclusivity/patent rules for that jurisdiction.
What should patients and clinicians expect?
If biosimilars launch, clinicians generally continue to focus on efficacy and safety comparable to the reference medicine, while payers may encourage switching for cost. In practice, treatment decisions can be influenced by:
- Whether the biosimilar is designated as interchangeable/substitutable (depends on jurisdiction).
- Hospital or payer policies for switching and prior authorization.
Sources
- https://www.drugpatentwatch.com/